RCS - Creo Medical Group - Attendance at Digestive Disease Week

Creo MedicalAnnouncement

15/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230515:nRSO3396Za&default-theme=true

RNS Number : 3396Z  Creo Medical Group PLC  15 May 2023

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Attendance at Digestive Disease Week

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of surgical endoscopy, updates on a hugely successful Digestive
Disease Week ("DDW"), the world's premier meeting for physicians, researchers
and industry in the fields of gastroenterology, hepatology, endoscopy and
gastrointestinal surgery, in Chicago, USA.

 

This year's DDW, which was attended by over 12,500 international delegates,
took place between 6-9 May 2023. Creo used the event to showcase its products
and technologies with the Company's Speedboat Inject device a headline
attraction.

 

Highlights from the event include:

 

-      A 288% year on year increase in sales leads directly from the
event (compared with 2022 DDW)

-      Booth visitors from 28 different countries

-      A dramatic increase in showcased poster presentations and lectures
focusing on the role of Speedboat Inject in endoscopic procedures, with one
shortlisted and presented at the primary presentation hall for the final day's
round up ASGE plenary session

-      Premier clinicians from across the globe attending Creo Medical's
'Advancing Energy in Third Space Endoscopy: Exploring New Possibilities'
symposium, held in conjunction with DDW, including world famous endoscopy
experts Prof Hinori Yamamoto and Prof Naohisa Yahagi from Japan

-      Exciting developments in progressing and finalising distribution
agreements for new territories

-      Providing many leading physicians with a first glimpse of
proto-types and pre-release devices behind closed doors

 

Creo Medical CEO Craig Gulliford said:

"DDW is an annual event bringing together the world's leading minds in the
fields of gastroenterology, hepatology, endoscopy and gastrointestinal
surgery, with this year's the most significant in our history.

 

"From presentations and lectures to interest and accolades, we are now seeing
Upper GI gastroenterologists, Lower GI Gastroenterologists, Foregut Surgeons,
Colorectal surgeons and a whole host besides demonstrating to their peers what
our advanced energy devices are delivering for healthcare providers and their
patients. It's a real step change in our presence over previous years."

 

David Woods, Chief Commercial Officer of Creo, added:

"It's fantastic to see the significant increase in sales leads, orders and
broader interest from every corner of the globe during and following what has
been a hugely productive DDW for Creo.

 

"Whilst DDW is one of the largest events in the US GI calendar, it is just one
of a number of key exhibitions Creo is attending this Spring including a busy
ESGE (European Society of Gastrointestinal Endoscopy Days 2023), which
occurred in late April, and several upcoming showcase events in the EMEA and
APAC over the coming weeks. At each, live Speedboat Inject case features and
hands-on experiences are shown, supported by renowned clinicians in the field,
underlining how the momentum and adoption of Creo's medtech is growing apace."

 

Enquiries:

 

 Creo Medical Group plc                              www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                  +44 (0)1291 606 005

 Cenkos Securities plc                               +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Sales)

 Numis Securities Limited (Joint Broker)             +44 (0)20 7260 1000

 Freddie Barnfield / James Black / Duncan Monteith

 Walbrook PR Ltd                                     Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen /                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 Phillip Marriage

 

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions.  CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFFLIEEISLIV